University of Crete (UOC)
Investigating the effects of platelets in diet-induced obesity and insulin resistance during atherosclerosis regression
Abstract
dc:descriptionCardiovascular diseases remain the leading cause of death globally, with atherosclerotic cardiovascular disease (ASCVD) being a significant contributor. Atherosclerosis, characterized by lipid accumulation and chronic inflammation within arterial walls, progresses through endothelial dysfunction, which facilitates lipid deposition and lesion formation. These lesions evolve into plaques that can rupture, leading to acute events like heart attacks and strokes. Despite advancements in lipid-lowering therapies, such as statins, residual cardiovascular risk remains particularly high in individuals with metabolic disorders, including obesity and type 2 diabetes (T2D). This highlights the need to investigate additional contributors to ASCVD, including platelet-mediated inflammatory pathways.Platelets, primarily known for their roles in hemostasis and thrombosis, also play pivotal roles in atherosclerosis by interacting with immune cells, forming aggregates, and exacerbating inflammation. Activated platelets promote leukocyte recruitment, enhance pro-inflammatory phenotypes, and modulate the microenvironment within atherosclerotic plaques. Platelet activation further amplifies inflammation by facilitating LDL uptake by macrophages, leading to foam cell formation, and enhancing IL-1β production through NF-κB signaling. This study examines the role of platelets in atherosclerosis regression, focusing on their impact on macrophage phenotypes and plaque composition during lipid-lowering treatment. The central hypothesis was that platelet activation in a diet-induced obesity and insulin resistance (DIO/IR) model would hinder atherosclerosis regression. Using this model, I explored the effects of platelet depletion on macrophages and plaque dynamics through single-cell transcriptomics, immunohistology, and functional assays.Lipid-lowering therapy did not significantly alter platelet activation or the metabolic characteristics of diabesity in mice. Specifically, obese mice undergoing lipid-lowering treatment retained IR and impaired glucose tolerance (iGT), regardless of platelet presence. Upon platelet depletion, key findings revealed notable changes in plaque composition and macrophage phenotypes. Plaque morphometric analysis showed improvements, including increased collagen area -a marker of plaque stability- while the CD68+ macrophage area remained constant. Single-cell RNA sequencing (scRNA seq) and immunostaining identified an increase in Fcgr4+ macrophages, a reparative population associated with enhanced phagocytic activity and reduced pro-inflammatory signaling, and a reduction in foamy macrophages, which exhibited a less inflammatory phenotype. These changes correlated with decreased necrotic core areas in platelet-deficient mice, highlighting the role of Fcgr4+ macrophages in promoting plaque stability. Collectively, these findings demonstrate the reparative shifts in plaque microenvironments induced by platelet depletion during lipid-lowering therapy, contributing to a more stable atherosclerotic plaque. Interestingly, platelet depletion did not affect circulating monocyte or neutrophil counts, suggesting that its impact is localized to the plaque microenvironment. The disruption of monocyte-platelet and neutrophil-platelet aggregates (MPA and NPA) in circulation likely contributes to these localized changes. Ex vivo experiments revealed that LPS stimulation inversely regulated Fcgr4 expression in macrophages while promoting pro-inflammatory cytokine production, underscoring a nuanced role for Fcgr4+ macrophages in plaque remodeling. Additional analyses revealed systemic effects of platelet depletion, including splenomegaly and alterations in hematopoietic stem and progenitor cells (HSPCs). Increased common myeloid progenitors (CMPs) in the spleen and bone marrow suggest compensatory responses to platelet loss, although these changes did not translate into altered circulating platelet or red blood cell counts. These findings underscore the complexity of platelet-mediated regulation of immune cell dynamics. Clinically, these results have significant implications for treating ASCVD, especially in high-risk populations such as those with obesity and T2D. Platelet-targeted therapies, combined with lipid-lowering agents, could synergistically reduce cardiovascular risk by addressing both lipid levels and inflammation. By elucidating the molecular mechanisms underlying platelet-leukocyte interactions, this study highlights the therapeutic potential of targeting platelets to enhance inflammation resolution and plaque stability in ASCVD. In conclusion, this work demonstrates that platelet depletion during lipid-lowering therapy significantly influences plaque macrophage phenotypes, fostering a reparative environment and stabilizing atherosclerotic plaques. These findings provide a comprehensive framework for understanding the interplay between platelets and immune cells in atherosclerosis regression and pave the way for developing innovative therapeutic strategies to reduce the burden of ASCVD in diverse patient populations.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Laskou, Maria
- Λάσκου, Μαρία
Subjects
dc:subject × 7Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61400